FindTrial
Sign In

Neflamapimod

DRUG9 trials

Sponsors

Eip Pharma Inc., EIP Pharma Inc

Conditions

2017)Alzheimer DiseaseDementia With Lewy BodiesDementia With Lewy Bodies (DLB)Dementia with Lewy Bodies (DLB)Huntington DiseaseIschaemic StrokeModerate to Severe Acute Ischaemic Stroke

Phase 2

Proof-of-Concept Study of a Selective p38 MAPK Alpha Inhibitor, Neflamapimod, in Subjects With Mild Alzheimer's Disease
CompletedNCT03402659
EIP Pharma IncAlzheimer Disease
Start: 2017-12-29End: 2019-07-31Updated: 2021-10-27
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
TerminatedNCT03980938
EIP Pharma IncHuntington Disease
Start: 2019-07-08End: 2020-10-15Updated: 2022-04-06
Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies
CompletedNCT04001517
EIP Pharma IncDementia With Lewy Bodies (DLB)
Start: 2019-09-30End: 2020-06-30Updated: 2023-06-29
RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
CompletedNCT05869669
EIP Pharma IncDementia With Lewy Bodies
Start: 2023-05-01End: 2025-06-16Updated: 2026-01-07
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
CompletedCTIS2023-504373-20-00
Eip Pharma Inc.2017), but the subject has historical polysomnography (PSG)-verified REM sleep behavioral disorder (RBD), including a positive DaTscan™ and a CDR Global Score of 0.5 or 1.0. If the DaTscan is negative +2
Start: 2023-08-09End: 2025-05-12Target: 15Updated: 2025-03-25
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)
Active, not recruitingCTIS2024-511446-39-00
Eip Pharma Inc.Dementia with Lewy Bodies (DLB)
Start: 2024-08-02Target: 25Updated: 2025-05-12
A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies
Active, not recruitingNCT06815965
EIP Pharma IncDementia With Lewy Bodies (DLB)
Start: 2024-10-16End: 2026-04-30Target: 25Updated: 2025-10-08
A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke
RecruitingNCT06987643
EIP Pharma IncIschaemic Stroke, Moderate to Severe Acute Ischaemic Stroke
Start: 2025-06-20End: 2026-06-28Target: 90Updated: 2026-02-09
Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia
RecruitingNCT07033481
EIP Pharma IncNonfluent Variant Primary Progressive Aphasia (nfvPPA)
Start: 2025-08-31End: 2026-10-31Target: 20Updated: 2025-08-28

Related Papers

Effects of neflamapimod (p38α kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer’s disease (AD) Co‐Pathology
Alzheimer s & Dementia2025-12-01
Neflamapimod treatment reduces plasma glial fibriallary acidic protein levels in patients with pure dementia with Lewy bodies (DLB)
Alzheimer s & Dementia2024-12-011 citations
Phase 2A Learnings Incorporated into RewinD-LB, a Phase 2B Clinical Trial of Neflamapimod in Dementia with Lewy Bodies.
2024-01-015 citations
Association of Plasma Phosphorylated Tau With the Response to Neflamapimod Treatment in Patients With Dementia With Lewy Bodies
Neurology2023-09-0120 citations
Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration.
2022-09-2140 citations
A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
2021-05-2773 citations